Abstract
Bronchiolitis obliterans (BO) is a serious noninfectious complication following an allogeneic bone marrow transplant (BMT). A 21-year-old female received an allogeneic BMT as a treatment for myelodyplastic syndrome. Four months after the BMT, progressive dyspnea developed and BO was also diagnosed by a lung biopsy. The patient was administered steroid and immunosuppressive agents for 1 year but there was no improvement in pulmonary function. Azithromycin was prescribed (500 mg q.d. for 3 days followed by 250 mg three time a week) because macrolides might decrease the inflammatory reaction leading to BO. The patient's pulmonary function improved after administration of azithromycin for 1 year. The forced expiratory volume in a one second (FEV1) increase was 220 mL (28.2%) and the forced vital capacity (FVC) increase was 460 mL (25.7%). We report the improvement in the pulmonary function after the administration of azithromycin for 1 year in a patient with BO after a BMT.
Figures and Tables
References
1. Roca J, Granena A, Rodriguez-Roisin R, Alvarez P, Agusti-Vidal A, Rozman C. Fatal airway disease in an adult with chronic graft-versus-host disease. Thorax. 1982. 37:77–78.
2. Soubani AO, Uberti JP. Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J. 2007. 29:1007–1019.
3. Marras TK, Chan CK. Obliterative bronchiolitis complicating bone marrow transplantation. Semin Respir Crit Care Med. 2003. 24:531–542.
4. Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J. 2005. 25:490–493.
5. Katzenstein AL. Katzenstein AL, editor. Chap 16. Miscellaneous II. Nonspecific inflammatory and destructive diseases. Surgical pathology of non-neoplastic lung disease. 2006. 4th ed. Philadelphia: Saunders;457–464.
6. Kim CJ, Kook H, Cho SH, Choi SH, Hwang MJ, Hwang TJ. Bronchiolitis obliterans and generalized vitiligo as rare presentations of chronic graft-versus-host disease. Korean J Pediatr Hematol-Onco. 1998. 5:207–215.
7. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001. 28:425–434.
8. Corrin B, Nicholson AG. Corrin B, Nicholson AG, editors. Chapter 3. Diseases of the airways. Pathophysiology of the lungs. 2006. 2nd ed. Philadelphia: Churchill Livingstone;119–122.
9. Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y, et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood. 2003. 102:4236–4242.
10. Au WY, Ho JC, Lie AK, Sun J, Zheng L, Liang R, et al. Respiratory ciliary function in bone marrow recipients. Bone Marrow Transplant. 2001. 27:1147–1151.
11. Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindeløv L, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood. 1999. 93:2196–2201.
12. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003. 168:121–125.
13. Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV, Eapen GA, et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008. 41:63–67.
14. Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004. 125:41S–50S.